WO2022025264A1 - ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 - Google Patents

ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 Download PDF

Info

Publication number
WO2022025264A1
WO2022025264A1 PCT/JP2021/028366 JP2021028366W WO2022025264A1 WO 2022025264 A1 WO2022025264 A1 WO 2022025264A1 JP 2021028366 W JP2021028366 W JP 2021028366W WO 2022025264 A1 WO2022025264 A1 WO 2022025264A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
synthetic peptide
acid sequence
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/028366
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
徹彦 吉田
菜穂子 ベイリー小林
善紀 吉田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toagosei Co Ltd
Kyoto University NUC
Original Assignee
Toagosei Co Ltd
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toagosei Co Ltd, Kyoto University NUC filed Critical Toagosei Co Ltd
Priority to JP2022539616A priority Critical patent/JP7747273B2/ja
Priority to EP21851571.6A priority patent/EP4190799A4/en
Priority to US18/007,092 priority patent/US20230272005A1/en
Priority to CN202180058673.0A priority patent/CN116157411A/zh
Publication of WO2022025264A1 publication Critical patent/WO2022025264A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to amino acid sequence information of a protein derived from SARS-CoV-2 and its utilization, which can contribute to the prevention and treatment of the spread of infection of the new type coronavirus (SARS-CoV-2, severe acute respiratory syndrome coronavirus 2).
  • SARS-CoV-2 new type coronavirus
  • severe acute respiratory syndrome coronavirus 2 severe acute respiratory syndrome coronavirus 2
  • SARS-CoV-2 is a virus that infects humans and causes COVID-19 (Coronavirus disease 2019), and is a pathogenic virus that rapidly causes severe symptoms such as pneumonia and may even kill infected people. Is. Since the discovery of an infectious disease caused by this virus from December 2019 to early 2020, the infection has spread throughout the world and is as serious to the world's economy and human life as the conventionally known SARS and MERS. It is an influential viral infection.
  • SARS-CoV-2 The genome sequence of SARS-CoV-2 is published in Non-Patent Document 1, and can be browsed in the database published by NCBI (National Center for Biotechnology Information). According to the database, it is predicted that at least 10 genes are present in the SARS-CoV-2 genome, and researchers in various fields such as virology, genetics, biochemistry, and pharmaceuticals are rapidly advancing research. ing.
  • the present invention has been made in view of the above-mentioned current situation, and its main purpose is to provide amino acid sequence information for producing an antibody against a protein derived from SARS-CoV-2.
  • the present invention provides a synthetic peptide having the amino acid sequence information and a composition comprising the synthetic peptide.
  • Another related object is to provide a method for producing an anti-SARS-CoV-2 antibody using the synthetic peptide or composition described above.
  • the present inventors analyzed the amino acid sequence encoded by the gene sequence existing in the genomic sequence of SARS-CoV-2 using SignalP-5.0, which is a signal peptide prediction software available on the web. As a result, we found three proteins that are predicted to have a signal peptide. And since the signal peptide is a necessary region for self-proliferation for the virus, the present inventors conserve the sequence of the signal peptide of SARS-CoV-2 that self-proliferates (that is, causes the spread of infection). It was estimated that there is a high possibility that it is.
  • the synthetic peptide disclosed here is a synthetic peptide recognized as an antigen for at least one kind of mammal, and contains any of the amino acid sequences of SEQ ID NOs: 1 to 3 and has a total number of amino acid residues. It is 20 or less.
  • the amino acid sequence is recognized as an exogenous foreign substance (antigen) by mammals, and therefore, when the synthetic peptide is administered to mammals, an antibody using the synthetic peptide as an antigen is produced.
  • composition disclosed here is a composition containing a moiety recognized as an antigen for at least one kind of mammal, which comprises any of the amino acid sequences of SEQ ID NOs: 1 to 3 and is total. It comprises a synthetic peptide having 20 or less amino acid residues and a carrier protein. According to this configuration, the carrier protein is large in size and highly complex, so that the immunogenicity of the synthetic peptide can be enhanced.
  • the carrier protein is bound to the C-terminal side or the N-terminal side of the amino acid sequence shown in any of SEQ ID NOs: 1 to 3 via a predetermined cross-linking agent. is doing. According to such a configuration, the synthetic peptide becomes a state farther from the surface of the carrier protein, and the probability that an antibody using the synthetic peptide as an epitope can be produced can be improved.
  • a method for producing an anti-SARS-CoV-2 antibody is provided. That is, the method for producing the anti-SARS-CoV-2 antibody disclosed herein utilizes the amino acid information according to any one of SEQ ID NOs: 1 to 3 as an antigen for producing the antibody. This makes it possible to produce an antibody against the predicted signal peptide sequence of the protein derived from SARS-CoV-2.
  • a preferred embodiment of the antibody production method disclosed herein utilizes the amino acid sequence information shown in SEQ ID NO: 1. This makes it possible to produce an antibody against the predicted signal peptide sequence of the protein derived from SARS-CoV, which has a particularly high antibody titer.
  • FIG. 1 shows a pre-immunization serum obtained in the process of administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 4 and keyhole limpet hemocianine (KLH) to a first rabbit multiple times. It is a graph which evaluated the antibody titer with respect to the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 4 of the serum for the second time and the second time evaluation.
  • FIG. 2 shows a second evaluation serum obtained by administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 4 and keyhole limpet hemocianine (KLH) to the first rabbit multiple times.
  • FIG. 3 shows a pre-immunization serum obtained in the process of administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 4 and keyhole limpet hemocianine (KLH) to a second rabbit multiple times. It is a graph which evaluated the antibody titer with respect to the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 4 of the serum for the second time and the second time evaluation.
  • KLH keyhole limpet hemocianine
  • FIG. 4 shows a second evaluation serum obtained by administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 4 and keyhole limpet hemocianine (KLH) to a second rabbit multiple times. It is a graph which evaluated the antibody titer with respect to the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 4 of the serum for the second evaluation and the serum prepared by total blood collection (serum at the time of total blood collection).
  • FIG. 5 shows a pre-immunization serum obtained in the process of administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 2 and keyhole limpet hemocianine (KLH) to a third rabbit multiple times.
  • FIG. 6 shows a second evaluation serum obtained by administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 2 and keyhole limpet hemocianine (KLH) to a third rabbit multiple times. It is a graph which evaluated the antibody titer with respect to the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 2 of the serum for the second evaluation and the serum prepared by total blood collection (serum at the time of total blood collection).
  • KLH keyhole limpet hemocianine
  • FIG. 7 shows a pre-immunization serum obtained in the process of administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 2 and keyhole limpet hemocianine (KLH) to a fourth rabbit multiple times. It is a graph which evaluated the antibody titer with respect to the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 2 of the serum for the second time and the second time evaluation.
  • FIG. 8 shows a second evaluation serum obtained by administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 2 and keyhole limpet hemocianine (KLH) to a fourth rabbit multiple times.
  • FIG. 9 shows a pre-immunization serum obtained in the process of administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 3 and keyhole limpet hemocianine (KLH) to a fifth rabbit multiple times. It is a graph which evaluated the antibody titer with respect to the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 3 of the serum for the second time and the second time evaluation.
  • KLH keyhole limpet hemocianine
  • FIG. 10 shows a second evaluation serum obtained by administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 3 and keyhole limpet hemocianine (KLH) to a fifth rabbit multiple times. It is a graph which evaluated the antibody titer with respect to the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 3 of the serum for the second evaluation and the serum prepared by total blood collection (serum at the time of total blood collection).
  • FIG. 11 shows a pre-immunization serum obtained in the process of administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 3 and keyhole limpet hemocianine (KLH) to a sixth rabbit multiple times.
  • FIG. 12 shows a second evaluation serum obtained by administering a composition comprising the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 3 and keyhole limpet hemocianine (KLH) to the sixth rabbit multiple times. It is a graph which evaluated the antibody titer with respect to the synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 3 of the serum for the second evaluation and the serum prepared by total blood collection (serum at the time of total blood collection).
  • KLH keyhole limpet hemocianine
  • amino acids may be represented by one-letter notation (however, three-letter notation in the sequence listing) based on the nomenclature for amino acids shown in the IUPAC-IUB guideline.
  • amino acids may be represented by one-letter notation (however, three-letter notation in the sequence listing) based on the nomenclature for amino acids shown in the IUPAC-IUB guideline.
  • all the contents of all the documents cited herein are incorporated herein by reference.
  • synthetic peptide means that the peptide chain does not exist independently and stably in nature, but is produced by artificial chemical synthesis or biosynthesis (that is, production based on genetic engineering).
  • a peptide fragment that can be stably present in a predetermined system for example, a composition containing an adjuvant.
  • peptide is a term that refers to an amino acid polymer having a plurality of peptide bonds, and is not limited by the number of amino acid residues contained in the peptide chain, but typically the total number of amino acid residues is approximately 100 or less. (Preferably 80 or less, more preferably 70 or less, for example 60 or less), which has a relatively small molecular weight.
  • amino acid residue as used herein is a term that includes the N-terminal amino acid and the C-terminal amino acid of the peptide chain, unless otherwise specified.
  • conjugate is a product (construction) in which a carrier protein and other components (crosslinking agent, Cys residue) are covalently linked to the synthetic peptide, and is disclosed herein. Is included in the composition.
  • the left side is always the N-terminal side and the right side is the C-terminal side.
  • the synthetic peptides disclosed herein contain a predictive signal peptide sequence of a protein encoded by the genome of SARS-CoV-2 published in NCBI. That is, the synthetic peptide has the following amino acid sequence: (1) MKFLVFLGIITTVAA (SEQ ID NO: 1); (2) MFVLVLLLPLVSSQC (SEQ ID NO: 2); (3) MKIILFLALITTLATC (SEQ ID NO: 3); Contains any of.
  • the amino acid sequence of SEQ ID NO: 1 corresponds to a predictive signal peptide consisting of a total of 15 amino acid residues derived from the protein of SARS-CoV-2, ORF8 protein.
  • the amino acid sequence of SEQ ID NO: 2 corresponds to a predictive signal peptide consisting of a total of 15 amino acid residues derived from the SARS-CoV-2 protein surface glycoprotein.
  • the amino acid sequence of SEQ ID NO: 3 corresponds to a predicted signal peptide consisting of a total of 15 amino acid residues derived from the protein of SARS-CoV-2, ORF7a protein.
  • amino acid sequences are unique to SARS-CoV-2, they are easily recognized as foreign foreign substances (antigens) by organisms including mammals, and the above synthetic peptides are administered to organisms including mammals. This can stimulate the production of antibodies against these amino acid sequences.
  • the synthetic peptide has a sequence other than the amino acid sequence of any of SEQ ID NOs: 1 to 3.
  • the C-terminal side of the amino acid sequence of SEQ ID NO: 1 contains an amino acid sequence encoded consecutively adjacent to the C-terminal side of the above-mentioned ORF8 protein predictive signal peptide.
  • the C-terminal side of the amino acid sequence of SEQ ID NO: 2 may contain an amino acid sequence encoded consecutively adjacent to the C-terminal side of the above-mentioned predictive signal peptide of surface glycoprotein.
  • the C-terminal side of the amino acid sequence of SEQ ID NO: 3 may contain an amino acid sequence encoded consecutively adjacent to the C-terminal side of the predicted signal peptide of ORF7a protein described above.
  • a sequence in which a Cys residue is added to the N-terminal side or the C-terminal side of the amino acid sequence of SEQ ID NO: 1, such as the amino acid sequences of SEQ ID NOs: 4 and 5, can be mentioned.
  • the amino acid sequence of SEQ ID NO: 4 is a sequence in which a Cys residue is added to the C-terminal side of a predictive signal peptide (SEQ ID NO: 1) consisting of a total of 15 amino acid residues derived from the protein of SARS-CoV-2, ORF8 protein. be.
  • the amino acid sequence of SEQ ID NO: 5 is a sequence in which a Cys residue is added to the N-terminal side of a predictive signal peptide (SEQ ID NO: 1) consisting of a total of 15 amino acid residues derived from the protein of SARS-CoV-2, ORF8 protein. be.
  • the thiol group (SH group) contained in the side chain of the Cys residue can be added.
  • the maleimide that can be contained in the cross-linking agent can be reacted, and the synthetic peptide and the cross-linking agent can be easily bound.
  • the total number of amino acid residues of the synthetic peptide disclosed here is 20 or less. If the amount is more than this, when administered to an organism such as a mammal, an antibody having an epitope other than the amino acid sequence of any one of SEQ ID NOs: 1 to 3 may be produced. Further, from the viewpoint of limiting the site to be an epitope, the total number of amino acid residues may be 19 or less, 18 or less, 17 or less, 16 or less, and is composed of only one of the amino acid sequences of SEQ ID NOs: 1 to 3. May be.
  • N-terminal amino group of the synthetic peptide disclosed here may be N-acetylated. Since the N-terminal amino acid residue is N-acetylated, the solubility of the synthetic peptide can be improved.
  • the synthetic peptide disclosed here can be easily produced according to a general chemical synthesis method. For example, either a conventionally known solid phase synthesis method or a liquid phase synthesis method may be adopted. A solid-phase synthesis method in which Boc (t-butyloxycarbonyl) or Fmoc (9-fluorenylmethoxycarbonyl) is applied as a protecting group for an amino group is suitable.
  • the synthetic peptide may be biosynthesized based on a genetic engineering technique. That is, a polynucleotide (typically DNA) of a nucleotide sequence (including the ATG start codon) encoding the amino acid sequence of the desired synthetic peptide is synthesized. Then, it includes various regulatory elements (promoter, ribosome binding site, terminator, enhancer, and various cis elements for controlling the expression level) for expressing the synthesized polynucleotide (DNA) and the amino acid sequence in the host cell. ), A recombinant vector having a gene construct for expression is constructed according to the host cell.
  • a polynucleotide typically DNA
  • various regulatory elements promoter, ribosome binding site, terminator, enhancer, and various cis elements for controlling the expression level
  • this recombinant vector is introduced into a given host cell (eg, yeast, insect cell, plant cell) and the host cell or tissue or individual containing the cell is cultured under predetermined conditions.
  • a given host cell eg, yeast, insect cell, plant cell
  • the target peptide can be expressed and produced intracellularly.
  • the target antiviral peptide can be obtained by isolating the peptide from the host cell (in the medium if it is secreted) and performing refolding, purification and the like as necessary.
  • the method for constructing the recombinant vector and the method for introducing the constructed recombinant vector into the host cell the methods conventionally used in the art may be adopted as they are, and the method itself is particularly disclosed here. Since it does not characterize the technology, detailed description is omitted.
  • a template DNA for a cell-free protein synthesis system that is, a synthetic gene fragment containing a nucleotide sequence encoding the amino acid sequence of a synthetic peptide
  • various compounds required for peptide synthesis ATP, RNA polymerase, amino acids, etc.
  • the so-called cell-free protein synthesis system can be adopted to synthesize the target polypeptide in vitro.
  • Shimizu et al. Shimizu et al., Nature Biotechnology, 19, 751-755 (2001)
  • Madin et al. Madin et al.
  • Single-stranded or double-stranded polynucleotides comprising a nucleotide sequence encoding a synthetic peptide disclosed herein and / or a nucleotide sequence complementary to the sequence shall be easily produced (synthesized) by a conventionally known method. Can be done. That is, by selecting the codon corresponding to each amino acid residue constituting the designed amino acid sequence, the nucleotide sequence corresponding to the amino acid sequence of the synthetic peptide is easily determined and provided. Then, once the nucleotide sequence is determined, a polynucleotide (single strand) corresponding to the desired nucleotide sequence can be easily obtained by using a DNA synthesizer or the like.
  • the obtained single-stranded DNA can be used as a template, and various enzymatic synthetic means (typically PCR) can be used to obtain the desired double-stranded DNA.
  • the polynucleotide may be in the form of DNA or may be in the form of RNA (mRNA or the like).
  • the DNA can be provided in double or single strands. When provided as a single strand, it may be a coding strand (sense strand) or a non-coding strand (antisense strand) having a complementary sequence.
  • the polynucleotide thus obtained can be used as a material for constructing a recombinant gene (expression cassette) for synthetic peptide production in various host cells or in a cell-free protein synthesis system. Can be done.
  • the synthetic peptide disclosed here is recognized as an antigen against at least one mammal, and can promote the production of an antibody (IgM, IgG, etc.) that recognizes the synthetic peptide.
  • the synthetic peptide may be in the form of a salt as long as it is recognized as an antigen by at least one mammal.
  • an acid addition salt of the peptide which can be obtained by an addition reaction with an inorganic acid or an organic acid usually used according to a conventional method, can be used.
  • it may be another salt (eg, a metal salt) as long as it is recognized as an antigen by at least one mammal.
  • peptides include those in such salt form.
  • the synthetic peptides disclosed herein are also provided as part of a composition comprising a carrier protein. That is, the composition disclosed herein is a composition containing a portion recognized as an antigen for at least one kind of mammal, and has the following amino acid sequence: (1) MKFLVFLGIITTVAA (SEQ ID NO: 1); (2) MFVLVLLLPLVSSQC (SEQ ID NO: 2); (3) MKIILFLALITTLATC (SEQ ID NO: 3); A synthetic peptide containing any of the above and having a total number of amino acid residues of 20 or less, and a carrier protein.
  • the type of carrier protein is not particularly limited, but for example, KLH (Keyhole limpet hemocyanin), OVA (ovalbumin), BSA (Bovine Serum Albumin), etc., which have antigenic stimulation, can be preferably used.
  • KLH Keyhole limpet hemocyanin
  • OVA ovalbumin
  • BSA Bovine Serum Albumin
  • a carrier protein is bound to the C-terminal side or the N-terminal side of the synthetic peptide via a predetermined cross-linking agent.
  • the cross-linking agent one having a homobifunctional group or a heterobifunctional group usually used for cross-linking a peptide can be used.
  • Preferred reactive functional groups of the cross-linking agent include various amine-containing compounds (eg, primary amines), thio or other sulfur-containing groups, carboxyls and hydroxyls. Specific examples of the reactive functional group include N-hydroxysuccinimide activated ester (NHS ester), maleimide, azide, iodoacetamide and the like.
  • the NHS ester can efficiently react with an amine at a pH of neutral or higher to form a very stable amide bond.
  • the above-mentioned maleimide has an SH group-selective reaction, and is superior in reactivity with an SH group in neutrality as compared with an amine.
  • Suitable cross-linking agents having a homobifunctional group include N-hydroxysuccinimide (NHS), dysuccinimidylsvelate (DSS), bis (sulfosuccinimidyl) svelate (BS3), dithiobis (succiniimi).
  • NHS N-hydroxysuccinimide
  • DSS dysuccinimidylsvelate
  • BS3 bis (sulfosuccinimidyl) svelate
  • dithiobis succiniimi
  • DSP dithiobis (sulfosuccinimidylpropionate)
  • DTSSP dithiobis (sulfosuccinimidylpropionate)
  • EGS ethylene glycol bis (succinimidylsuccinate)
  • Sulfo-EGS ethylene glycol bis (sulfosuccinimidylsuccinate) )
  • DST disulfosuccinimidyl tartrate
  • sulfo-DST disulfosuccinimidyl tartrate
  • BS 3 bis (sulfosuccinimidyl) svelate
  • BS 3 bis (sulfosuccinimidyl) svelate
  • a suitable cross-linking agent having a heterobifunctional group O- [N- (3-maleimidepropionyl) aminoethyl] -O'- [3- (N-succinimidyloxy) -3-oxo Polyethylene glycol (PEG) derivatives such as propyl] heptacosae ethylene glycol, m-maleimidebenzoyl-N-hydroxysuccinimide ester (MBS), succinimidyl 4- [maleimidephenyl] butyrate (SMPB), succinimidyl 4- (maleimidemethyl).
  • PEG polyethylene glycol
  • Cyclohexane-1-carboxylate SMCC
  • N- ( ⁇ -maleimidebutyroxy) succinimide ester GMBS
  • MPS m-maleimidepropionic acid-N-hydroxysuccinimide ester
  • N-succinimidyl (4-iodoacetyl) Aminobenzoate
  • SCC Cyclohexane-1-carboxylate
  • GMBS N- ( ⁇ -maleimidebutyroxy) succinimide ester
  • MPS m-maleimidepropionic acid-N-hydroxysuccinimide ester
  • N-succinimidyl (4-iodoacetyl) Aminobenzoate
  • PEG having NHS ester and maleimide as reactive functional groups
  • PEG has the property of showing little immunogenicity.
  • PEG is difficult to decompose in liquids in the human body. Therefore, a conjugate having a cross-linking agent containing PEG can be
  • the position where the synthetic peptide and the cross-linking agent bind is not particularly limited, but the N-terminal side or the C-terminal side is preferable. As a result, the synthetic peptide becomes more distant from the surface of the carrier protein, and the probability that an antibody using the synthetic peptide as an epitope can be produced can be improved.
  • the cross-linking agent binds to the N-terminal side of the synthetic peptide, if there is no amino group other than the N-terminal amino group in the synthetic peptide sequence (that is, if there is no Lys residue), for example.
  • the NHS ester contained in the cross-linking agent can be efficiently reacted with the N-terminal amino group of the synthetic peptide.
  • the thiol group of the Cys residue can be selectively reacted with the maleimide contained in the cross-linking agent, so that the binding of the cross-linking agent can be performed.
  • the position to be used can be the N-terminal or the C-terminal.
  • a Cys residue may be added to the N-terminal or C-terminal. This makes it possible to bind a cross-linking agent having maleimide to the N-terminal or C-terminal.
  • Synthetic peptides or compositions comprising the amino acid sequence set forth in any of SEQ ID NOs: 1-3 disclosed herein can be used to produce anti-SARS-CoV-2 antibodies.
  • a vaccine can be mentioned, and it can be used for vaccination against SARS-CoV-2, a therapeutic agent, and the like.
  • the above synthetic peptide and composition may be administered to an organism such as a mammal as an antigen to produce an antibody that recognizes the synthetic peptide.
  • an organism such as a mammal as an antigen to produce an antibody that recognizes the synthetic peptide.
  • mammal to be immunized experimental animals such as guinea pigs, rats, mice, rabbits and sheep are used, but rats, mice and rabbits are suitable for obtaining monoclonal antibodies or polyclonal antibodies.
  • any administration route such as subcutaneous, intraperitoneal, intravenous, intramuscular, or intradermal administration may be used, but it is preferable to inject mainly subcutaneously, intracutaneously, intraperitoneally, or intravenously. ..
  • immunization is performed about 2 to 10 times at 2-week intervals, and about 1 to 5 times, preferably about 1 to 5 times after the final immunization.
  • a method of collecting a sample from the living body after about 2 to 7 days is widely used.
  • the amount of immunity does not limit the amount of peptide to be administered at one time, but for example, it is preferable to use about 50 to 300 ⁇ g per rabbit.
  • a conjugate containing a synthetic peptide and a carrier protein is well mixed with an adjuvant (for example, FCA (Freund's complete adjuvant)) and administered intraperitoneally to mice to administer the cells.
  • FCA Fully Freund's complete adjuvant
  • Antibodies to the above synthetic peptide by growing and again mixing the conjugate with an adjuvant (eg, FCA or FIA (Freund's incomplete adjuvant)) and administering it intraperitoneally at 2-week intervals and collecting ascites. Highly valuable monoclonal antibodies or polyclonal antibodies can be efficiently obtained. Purification of the desired monoclonal antibody or polyclonal antibody can be performed by a known method such as affinity chromatography, ion exchange chromatography, gel filtration method, and sulfur salting out method.
  • an adjuvant eg, FCA or FIA (Freund's incomplete adjuvant)
  • the synthetic peptides and compositions disclosed herein may comprise a variety of pharmaceutically acceptable carriers, depending on the form of use, provided that the synthetic peptide is recognized as an antigen by at least one mammal.
  • carriers generally used in peptide-based drugs can be applied as diluents, excipients and the like.
  • the carrier may vary depending on the use and form of the synthetic peptide and composition containing the carrier, and examples of the carrier include water, physiological buffers, and various organic solvents. It can also be a non-drying oil such as an aqueous solution of an alcohol (ethanol or the like) having an appropriate concentration, glycerol, or olive oil. Alternatively, it may be a liposome.
  • examples of the secondary components that can be contained in the above composition include various fillers, bulking agents, binders, wetting agents, surfactants, pigments, fragrances, adjuvants and the like.
  • Typical forms of synthetic peptides and compositions containing the carriers include liquids, suspensions, emulsions, aerosols, foams, granules, powders, tablets, capsules, ointments, aqueous gels and the like.
  • it since it is used for injection or the like, it can be used as a freeze-dried product or a granulated product for preparing a drug solution by dissolving it in physiological saline or an appropriate buffer solution (for example, PBS) immediately before use.
  • compositions (drugs) using synthetic peptides (main components) and various carriers (secondary components) as materials may follow a conventionally known method, and the manufacturing method itself may be described here. Since it does not characterize the technology disclosed in the above, detailed description thereof will be omitted. Detailed sources of prescribing information include, for example, Comprehensive Medicinal Chemistry, supervised by Corwin Hansch, published by Pergamon Press (1990). The entire contents of this book are incorporated herein by reference.
  • Peptides having the amino acid sequences shown in Table 1 were produced using commercially available peptide synthesizers. Specifically, it is as follows.
  • Sample 1 is a synthetic peptide of the amino acid sequence shown in SEQ ID NO: 4, and is a synthetic peptide in which a Cys residue is added to the C-terminal side of the amino acid sequence of SEQ ID NO: 1.
  • Sample 2 is a synthetic peptide having the amino acid sequence shown in SEQ ID NO: 2.
  • Sample 3 is a synthetic peptide having the amino acid sequence shown in SEQ ID NO: 3.
  • the cross-linking agent is bound to the surface of the KLH, and then the maleimide of the cross-linking agent is reacted with the thiol group of the Cys residue present on the C-terminal side of the synthetic peptide to bind to each synthetic peptide.
  • a conjugate in which KLH was bound via PEG was prepared.
  • conjugates were prepared in the same manner as in Sample 1.
  • a composition obtained by mixing 0.15 mg of the conjugate of Sample 1 and an equal volume of FCA (Freund's complete adjuvant) was intradermally administered (first intradermal administration) to the rabbit.
  • a composition obtained by mixing 0.3 mg of the conjugate of Sample 1 and an equal volume of FCA was intradermally administered (second administration) to the rabbit.
  • a composition obtained by mixing 0.3 mg of the conjugate of Sample 1 and an equal volume of FCA was intradermally administered (third dose) to the rabbit.
  • 5 ml of trial blood was collected from the above rabbit, and the serum for the first evaluation was prepared.
  • a composition obtained by mixing 0.3 mg of the conjugate of Sample 1 and an equal volume of FCA was intradermally administered (sixth administration) to the rabbit.
  • all blood was collected from the above rabbits, and serum was prepared at the time of total blood collection.
  • Sodium azide was added to the prepared pre-immunization serum, the serum for the 1st to 3rd evaluation, and the serum at the time of total blood sampling so as to be 0.09% at the time of preparation and stored.
  • the conjugates of Samples 2 and 3 were also administered to 2 rabbits by the same method as that of Sample 1, and pre-immunity serum, serum for 1st to 3rd evaluation, and serum at the time of total blood sampling were prepared.
  • the two rabbits to which the conjugate of Sample 2 was administered were designated as the third rabbit and the fourth rabbit, respectively, and the two rabbits to which the conjugate of Sample 3 was administered were the first rabbits, respectively. Let's say the fifth rabbit and the sixth rabbit.
  • the antibody titers of the pre-immune serum, the serum for the first to third evaluations, and the serum at the time of total blood sampling were evaluated by the ELISA (Enzyme-Linked ImmunoSorbent Assay) method.
  • the synthetic peptide of Sample 1 was dissolved in PBS (Phosphate-Buffered Saline) having a pH of 7.2 so as to be 5 ⁇ g / ml, 100 ⁇ l was added to each well of the immunoplate, and the mixture was incubated at room temperature for 2 hours.
  • PBS Phosphate-Buffered Saline
  • FIGS. 1 to 4 show the results of the ELISA method of serum obtained from the first rabbit, and FIGS. 3 and 4 show the results of the ELISA method of serum obtained from the second rabbit.
  • the antibody titers of the pre-immunization sera of Samples 2 and 3 and the serum for the first to third evaluations and the serum at the time of total blood sampling were evaluated by the same method as the evaluation of the antibody titer of the serum of Sample 1.
  • the results are shown in FIGS. 5 to 12.
  • 5 and 6 show the results of the ELISA method of serum obtained from the third rabbit
  • FIGS. 7 and 8 show the results of the ELISA method of serum obtained from the fourth rabbit.
  • FIGS. 9 and 10 show the results of the ELISA method of serum obtained from the fifth rabbit
  • FIGS. 11 and 12 show the results of the ELISA method of serum obtained from the sixth rabbit.
  • the absorbance at 490 nm exceeds 0.5, it is evaluated that the antibody titer is guaranteed (has a good antibody titer). Further, when the absorbance exceeds the measurement upper limit of Immuno Reader (when the absorbance exceeds 3.0), the absorbance is indicated as 3.0.
  • the third rabbit could not obtain a serum in which the antibody titer against the synthetic peptide of sample 2 was guaranteed even after repeated administration of the conjugate of sample 2.
  • serum having an absorbance of more than 0.5 could be obtained in the fourth rabbit. Therefore, it was confirmed that administration of the conjugate of Sample 2 yields a serum containing an IgG antibody whose antibody titer against the synthetic peptide of Sample 2 is guaranteed.
  • the fifth rabbit could not obtain a serum in which the antibody titer against the synthetic peptide of sample 3 was guaranteed even after repeated administration of the conjugate of sample 3.
  • the sixth rabbit repeated administration of the conjugate of Sample 3 was able to obtain a result far exceeding 0.5 absorbance in the serum at the time of total blood sampling. rice field. Therefore, it was confirmed that administration of the conjugate of Sample 3 can obtain a serum containing an IgG antibody whose antibody titer against the synthetic peptide of Sample 3 is guaranteed. ..
  • the synthetic peptide and composition (conjugate) disclosed here can be used as vaccines against SARS-CoV-2.
  • the produced antibody can be an antiviral agent against SARS-CoV-2, and can be used for detection of SARS-CoV-2, labeling, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2021/028366 2020-07-31 2021-07-30 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 Ceased WO2022025264A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2022539616A JP7747273B2 (ja) 2020-07-31 2021-07-30 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
EP21851571.6A EP4190799A4 (en) 2020-07-31 2021-07-30 Amino acid sequence derived from sars-cov-2 and use thereof
US18/007,092 US20230272005A1 (en) 2020-07-31 2021-07-30 Amino Acid Sequence Derived from Sars-Cov-2 and Use Thereof
CN202180058673.0A CN116157411A (zh) 2020-07-31 2021-07-30 SARS-CoV-2衍生氨基酸序列及其应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-131022 2020-07-31
JP2020131022 2020-07-31

Publications (1)

Publication Number Publication Date
WO2022025264A1 true WO2022025264A1 (ja) 2022-02-03

Family

ID=80035853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/028366 Ceased WO2022025264A1 (ja) 2020-07-31 2021-07-30 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用

Country Status (5)

Country Link
US (1) US20230272005A1 (https=)
EP (1) EP4190799A4 (https=)
JP (1) JP7747273B2 (https=)
CN (1) CN116157411A (https=)
WO (1) WO2022025264A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023283412A1 (en) * 2021-07-09 2023-01-12 Atossa Therapeutics, Inc. Compositions and methods to increase coronavirus immune response

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020028219A (ja) * 2016-11-11 2020-02-27 大日本住友製薬株式会社 マラリアワクチン
JP2020131022A (ja) 2019-02-19 2020-08-31 キヤノンメディカルシステムズ株式会社 神経活動の領域を推定する推定方法、推定装置及び磁気共鳴イメージング装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1609119A (zh) * 2003-10-23 2005-04-27 中国医学科学院药物研究所 一种肽文库、其合成方法及从该文库中筛选的活性片段
BR102019017792A2 (pt) * 2019-08-27 2021-11-16 Fundação Oswaldo Cruz Receptáculo proteico, método para produção do receptáculo, método de identificação de patógenos ou de diagnóstico de doenças, e, uso do receptáculo
JP2023512519A (ja) * 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
WO2021181390A1 (en) * 2020-03-09 2021-09-16 Vaxil Biotherapeutics Ltd. Antigen specific epitope–based anti-infective vaccines
TW202200199A (zh) * 2020-03-20 2022-01-01 美商百歐恩泰美國公司 冠狀病毒疫苗及使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020028219A (ja) * 2016-11-11 2020-02-27 大日本住友製薬株式会社 マラリアワクチン
JP2020131022A (ja) 2019-02-19 2020-08-31 キヤノンメディカルシステムズ株式会社 神経活動の領域を推定する推定方法、推定装置及び磁気共鳴イメージング装置

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CORWIN HANSCH: "Comprehensive Medicinal Chemistry", 1990, PERGAMON PRESS
KHAN M. IMRAN, HASAN KAZI NADIM, SUFIAN ABU, HOSEN M. BAYEJID, POLOL MOHAMMED NAFIZ IMTIAZ, KHALEQUE M. ABDUL, RAHMAN M. MIZANUR, : "Reports of Coding-Complete Genome Sequences of Five 2019 Novel Coronavirus (SARS-CoV-2) Strains Isolated in Bangladesh", GENOME ANNOUNCEMENTS, AMERICAN SOC. FOR MICROBIOLOGY, US, vol. 9, no. 31, 30 July 2020 (2020-07-30), US , pages 1 - 2, XP055890939, ISSN: 2169-8287, DOI: 10.1128/MRA.00692-20 *
MADIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, no. 2, 2000, pages 559 - 564
MISHRA SEEMA: "T cell epitope-based vaccine design for pandemic novel coronavirus 2019-nCoV across structural and non-structural proteins", CHEMRXIV, CAMBRIDGE OPEN ENGAGE, 3 April 2021 (2021-04-03), XP055851681, [retrieved on 20211015], DOI: 10.26434/chemrxiv.12029523.v2 *
See also references of EP4190799A4
SHIMIZU ET AL., NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 751 - 755
SINGH ABHISHEK, THAKUR MUKESH, SHARMA LALIT KUMAR, CHANDRA KAILASH: "Designing a multi-epitope peptide-based vaccine against SARS-CoV-2", BIORXIV, 16 April 2020 (2020-04-16), pages 1 - 25, XP055890934, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.04.15.040618v1.full.pdf> [retrieved on 20220214], DOI: 10.1101/2020.04.15.040618 *
UL QAMAR MUHAMMAD TAHIR, REHMAN ABDUR, ASHFAQ USMAN ALI, AWAN MUHAMMAD QASIM, FATIMA ISRAR, SHAHID FARAH, CHEN LING-LING: "Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches", BIORXIV, 22 March 2020 (2020-03-22), pages 1 - 36, XP055890937, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.02.28.970343v2.full.pdf> [retrieved on 20220214], DOI: 10.1101/2020.02.28.970343 *
WU, F. ET AL., NATURE, vol. 579, no. 7798, 2020, pages 265 - 269
YOSHIDA SHOTA, ONO CHIKAKO, HAYASHI HIROKI, SHIRAISHI SATOSHI, TOMONO KAZUNORI, ARASE HISASHI, MATSUURA YOSHIHARU, NAKAGAMI HIRONO: "SARS-CoV-2-induced humoral immunity through B cell epitope analysis and neutralizing activity in COVID-19 infected individuals in Japan", BIORXIV, 23 July 2020 (2020-07-23), pages 1 - 28, XP055890935, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.07.22.212761v1.full.pdf> [retrieved on 20220214], DOI: 10.1101/2020.07.22.212761 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023283412A1 (en) * 2021-07-09 2023-01-12 Atossa Therapeutics, Inc. Compositions and methods to increase coronavirus immune response

Also Published As

Publication number Publication date
JP7747273B2 (ja) 2025-10-01
EP4190799A1 (en) 2023-06-07
US20230272005A1 (en) 2023-08-31
CN116157411A (zh) 2023-05-23
EP4190799A4 (en) 2024-08-21
JPWO2022025264A1 (https=) 2022-02-03

Similar Documents

Publication Publication Date Title
Lairmore et al. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction
DE69518838T2 (de) Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung
JP2003529319A (ja) ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
ES2281900T3 (es) Peptidos sinteticos y vacunas que los contienen.
FR2655990A1 (fr) Agent viral responsable de l&#39;hepatite non-a non-b et polypeptides derives de celui-ci utiles pour le diagnostic et la vaccination.
Tian et al. Structure− affinity relationships in the gp41 ELDKWA epitope for the HIV‐1 neutralizing monoclonal antibody 2F5: effects of side‐chain and backbone modifications and conformational constraints
JP5187883B2 (ja) 抗原ペプチドおよびその利用
CA1327096C (en) Peptides corresponding to antigenic and immunogenic determinants of major neutralizing proteins of rotaviruses
AU636735B2 (en) Synthetic polypeptides
JPH02503916A (ja) Ｈｉｖエンベロープ蛋白質に関連する合成ペプチド
WO2023009028A1 (ru) Однодоменное антитело и его модификации, специфически связывающиеся с rbd s белка вируса sars-cov-2
US7435721B2 (en) Transport peptides such as C-terminal Erns peptide and analogues thereof
CA2297408C (en) Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
JP7747273B2 (ja) ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
CN116496389A (zh) 用于治疗hbv感染及相关疾病的表位肽及抗体
Villén et al. Functional mimicry of a discontinuous antigenic site by a designed synthetic peptide
JPH07509221A (ja) 自己抗体診断用の方法および試薬
JP7598538B2 (ja) ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
FI111731B (fi) Immuunikatoviruksen endonukleaasiproteiinista johdetut polypeptidit ja niiden käyttö diagnostiikassa
EP3892298A1 (en) Epitopes having sequence homology to coronavirus spike protein subunit and uses thereof
Du et al. Structural and immunological characterisation of heteroclitic peptide analogues corresponding to the 600–612 region of the HIV envelope gp41 glycoprotein
JPH07501710A (ja) エプスタイン・バールウイルスのペプチド及びこれらのペプチドに対する抗体
Sundaram et al. Structural and immunogenicity analysis of chimeric B‐cell epitope constructs derived from the gp46 and gp21 subunits of the envelope glycoproteins of HTLV‐1
Raupach et al. Elucidation of linear epitopes of pertussis toxin using overlapping synthetic decapeptides: identification of a human B-cell determinant in the S1 subunit indicative of acute infections
EP4393947A1 (en) Anti-pd-1 signal peptide antibody and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21851571

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022539616

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2021851571

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2021851571

Country of ref document: EP

Effective date: 20230228

NENP Non-entry into the national phase

Ref country code: DE